Benitrobenrazide (Hexokinase 2 inhibitor 1)通过直接靶向HK2来抑制糖酵解。
Cas No.:2454676-05-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Benitrobenrazide (Hexokinase 2 inhibitor 1) inhibits glycolysis by directly targeting HK2. Benitrobenrazide can induce apoptosis and promote the production of reactive oxygen species to inhibit cancer cell proliferation. Benitrobenrazide can be used in research related to pancreatic cancer and colorectal cancer[1-4].
In vitro, HepG2 and HUH7 human liver cancer cells were treated with Benitrobenrazide (15μM or 57.1μM) for 72 hours. Benitrobenrazide caused DNA damage, increased reactive oxygen species (ROS) production, and disrupted cell cycle progression. Its inhibitory effect may be related to HK2 inhibition and compound aggregation effects[1]. The Hu1545 human hepatocyte cell line was co-treated with Benitrobenrazide (10μM or 30μM) and 400μM palmitate for 8 hours. Benitrobenrazide significantly attenuated palmitate-induced lipid droplet accumulation (steatosis)[2].
In vivo, Benitrobenrazide (200mg/kg) was administered orally once daily for 21 days to BALB/c nude mice bearing MDA-MB-231 tumor xenografts. Benitrobenrazide significantly inhibited tumor growth and did not cause obvious toxic reactions[3].
References:
[1] Juszczak K, Kubicka A, Kitel R, et al. Hexokinase 2 Inhibition and Biological Effects of BNBZ and Its Derivatives: The Influence of the Number and Arrangement of Hydroxyl Groups. Int J Mol Sci. 2022 Feb 27;23(5):2616.
[2] Daniel PV, Puri G, Luo Y, et al. Silencing of S100A11 attenuates murine metabolic dysfunction-associated steatohepatitis. NPJ Gut Liver. 2025;2(1):32.
[3] Zheng M, Wu C, Yang K, et al. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. Pharmacol Res. 2021 Feb;164:105367.
[4] Al-Jabiri MH, Anshasi MA, Ma J, et al. Shapes of Benzyl Benzoate: A Rotational Spectroscopic and Computational Study. J Phys Chem A. 2026 Mar 19;130(11):2443-2450.
Benitrobenrazide (Hexokinase 2 inhibitor 1)通过直接靶向HK2来抑制糖酵解。Benitrobenrazide可诱导细胞凋亡和促进活性氧产生以抑制癌细胞增殖。Benitrobenrazide可用于胰腺癌和结直肠癌的相关研究[1-4]。
在体外，Benitrobenrazide（15μM或57.1μM）处理HepG2和HUH7人肝癌细胞72小时。Benitrobenrazide可导致DNA损伤、增加活性氧（ROS）产生并扰乱细胞周期进程，其抑制作用可能与抑制HK2及化合物聚集效应相关[1]。Benitrobenrazide（10μM或30μM）与400μM棕榈酸共处理Hu1545人肝癌细胞系8小时。Benitrobenrazide可显著减轻棕榈酸诱导的脂质积累（脂肪变性）[2]。
在体内，Benitrobenrazide（200mg/kg）每日一次口服给药于携带MDA-MB-231肿瘤异种移植的BALB/c裸鼠21天。Benitrobenrazide显著抑制了肿瘤生长，且未引起明显的毒性反应[3]。
| Cell experiment [1]: | |
Cell lines | Hu1545 human hepatocyte cell line (derived from human Telomerase Reverse Transcriptase (hTERT)-mediated immortalization) |
Preparation Method | Hu1545 cells were treated with palmitate (PA) at 400μM with or without the selective Benitrobenrazide (10μM or 30μM). |
Reaction Conditions | 10μM or 30μM; 8h. |
Applications | Benitrobenrazide significantly attenuated palmitate-induced lipid droplet accumulation (steatosis). |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice bearing MDA-MB-231 tumor xenografts |
Preparation Method | Benitrobenrazide was administered orally to tumor-bearing mice. |
Dosage form | 200mg/kg; p.o.; once daily for 21 days. |
Applications | Benitrobenrazide significantly inhibited tumor growth and did not cause obvious toxicity. |
References: | |
| Cas No. | 2454676-05-0 | SDF | |
| 分子式 | C14H11N3O6 | 分子量 | 317.25 |
| 溶解度 | DMSO : 125 mg/mL (394.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1521 mL | 15.7604 mL | 31.5209 mL |
| 5 mM | 630.4 μL | 3.1521 mL | 6.3042 mL |
| 10 mM | 315.2 μL | 1.576 mL | 3.1521 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet